LGR4 and ovarian carcinoma: These findings indicate that ALYREF promotes cisplatin resistance in ovarian cancer by recognizing m5C-modified sites on LGR4 mRNA, thereby enhancing its stability, facilitating nuclear export, and activating the Wnt/β-catenin pathway (Fig. 8).